ProTrans

DRUG2 trials

Sponsors

Region Uppsala, NextCell Pharma Ab

Conditions

Type 1 diabetesType1diabetes

Phase 1

Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed with Type I Diabetes

CompletedNCT03973827

NextCell Pharma AbType1diabetes

Start: 2019-05-17End: 2024-11-20Updated: 2025-03-07

Phase 2

A double-blinded, Randomized, Parallel, Placebo-controlled trial of Wharton´s Jelly-derived Allogenic Mesenchymal Stromal Cells to treat Type I Diabetes in Children Adolescents (WJMSC-P01)

Not yet recruitingCTIS2024-518270-14-00

Region UppsalaType 1 diabetes

Target: 66Updated: 2025-04-02

Related Papers

1997-LB: Repeated Infusion of the Mesenchymal Stromal Cell Product ProTrans Slows Type 1 Diabetes Disease Progression and Promotes Wider Health Benefits

Diabetes2025-06-13